Introduction
Neurosensory, maternally inherited, nonsyndromic deafness is a disease that may be provoked by specific mutations in mitochondrial DNA (mtDNA). The most plasmy. These studies have proposed that the level of heteroplasmy could influence the clinical manifestations of the disease [del Castillo et al., 2003; el Schahawi et al., 1997] .
Cosegregation with other mtDNA Mutations
Polymorphisms in mtDNA could influence the penetrance of pathogenic mutations responsible for other mitochondrial disorders. For example, it is thought that primary pathogenic mutations exist in Leber's disease and that secondary mutations, which are not intrinsically pathogenic, influence the expression of the primary mutations [Torroni et al., 1997] . It was proposed that various alterations in the mtDNA sequence may modulate the phenotypic expression of the A1555G mutation [Finnila et al., 2001; Li et al., 2004; Pandya et al., 1999] . Other alterations in the mitochondrial genome that cause neurosensory nonsyndromic deafness and that could cosegregate with A1555G are the changes A7445G, 7472 insC, T7510C, T7511C [Fischel-Ghodsian, 1999] or C1494T [Zhao et al., 2004] .
Nuclear Genes
Nuclear genes may also be candidates to functionally interact with and modify the mutated 12S rRNA, influencing the phenotypic expression of the A1555G mutation. Genome linkage studies propose that a locus in chromosome 8 might be linked to the disease [Bykhovskaya et al., 1998 [Bykhovskaya et al., , 2000 , but this linkage has not been replicated and no mutations have been found in the proposed modifying genes. Studies in the yeast Saccharomyces cerevisae have proposed the MTO1, MSS1 and MTO2 genes as strong candidates to modulate the effect of the mutation. Accordingly, MTO2 can complement the respiratory-deficient phenotype of yeast cells carrying the C1409G mutation in the 15S rRNA. Indeed, a G28T missense mutation in the TRMU gene (a homologue of MTO2) was identified in 613 subjects with nonsyndromic deafness from families of different ethnic origins, altering a conserved amino acid (alanine). Functionally, this mutation does not affect the import of TRMU precursors, but it does lead to a marked failure in mitochondrial tRNA metabolism [Guan et al., 2006] . These findings support the role of TRMU as a modulating factor of deafness-associated A1555G mutation.
In the current study, we analyzed possible modifying factors in 2 families carrying the A1555G mutation in which deafness was observed, in order to explain the differences in the phenotype between the carriers of the mutation. In these families, the heteroplasmy of the mutations was studied, as well as their cosegregation with other mitochondrial mutations in the 12S gene, and the proposed linkage with a region in chromosome 8 as well as with the TRMU and MTO1 sequences.
Methods
The 2 families examined in this study were of Spanish origin and were partially described in another study [el Schahawi et al., 1997] . All individuals studied were interviewed at the Neurology Service of the Hospital Donostia. Of 38 individuals in these families (18 male, 20 female), 19 (9 males, 10 females) were diagnosed with neurosensory nonsyndromic deafness.
Molecular Studies
After obtaining informed consent from each subject, DNA was extracted from peripheral blood by standard methods [Miller et al., 1988] . The control samples were taken from a DNA bank maintained by the Neurology Service of the Hospital Donostia and these controls were from individuals that did not suffer any neurological complaint.
Study of the A1555G Mutation
The presence of the A1555G mutation was determined by PCR-RFLP [el Schahawi et al., 1997] . A 94-bp fragment was amplified using a reverse mismatch primer that generated a novel restriction site in conjunction with the mutation. The presence or absence of the mutation could therefore be determined by complete digestion of the PCR product O/N with the restriction enzyme Hae III (New England Biolabs), and by analyzing the digestion products by electrophoresis in a 4% agarose gel. The novel restriction site generated by the presence of the mutated allele (1555G) gives rise to 2 bands of 64 and 30 bp upon digestion, while the normal allele (1555A) is not digested by the enzyme and thus, a 94-bp band is detected. In this way the carriers of the mutation can be easily differentiated.
Quantification of the Heteroplasmy Level
The level of heteroplasmy in mitochondrial mutations has classically been measured by densitometry of the bands obtained in 32 P-labeled RFLP studies. Since it is not currently clear which is the best technique to measure heteroplasmy [Bai and Wong, 2004; Jacobi et al., 2001] , we have used the following 2 methods to measure this phenomenon. -The first method involved capillary electrophoresis of the PCR-RFLP products in an ABIPRISM 310 analyzer. As noted above, the reverse mismatch primer creates a new Hae III target when the DNA carries the mutation while the forward primer was labeled with TAMRA. Two different peaks were detected after O/N enzyme digestion, the wild-type peak (94 bp) and the mutated peak (64 bp). In the heteroplasmic subjects, the proportion of the mutated molecules was estimated by the relation between the peaks' areas using the Genescan and Genotyper softwares (Applied Biosystems). Each digestion product was run twice and each digestion was performed 3 times from 3 independent PCR reactions. The percentage heteroplasmy was calculated as the mean of the 6 results. 
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-The other method relied on qPCR single nucleotide polymorphism (SNP) detection technology, using a 7300 qPCR genetic analyzer (Applied Biosystems) and an SNP assay with probes specifically designed by Applied Biosystems to detect the A1555G SNP. To establish the level of heteroplasmy, the threshold cycle of each probe (normal and mutated) was compared [Bai and Wong, 2004] using SDS, version 1.3.1 (Applied Biosystems). We checked each probe in 45 healthy controls to be sure that the mutated probe was sufficiently specific. Each assay was repeated 3 times and the value presented corresponds to the mean of these 3 measurements.
Study of the Mitochondrial Variations
By sequencing a 1141-bp amplicon of mtDNA that includes the MTRNR1 gene (see primers in table 1 ), we studied an affected individual and a carrier of the mutation in each family (individual III-11 of family 1 and IV-3 of family 2), as well as 3 control individuals.
Likewise, the mitochondrial mutations 961 insC, G7444A, A7445G, 7472 insC, T7510C, T7511C and C1494T were studied in all family members (affected and unaffected). The A4336G alteration was analyzed by PCR-RFLP with the enzyme Nla III (New England Biolabs) rather than by sequencing. The 4336A allele generates a 313-bp fragment, while the allele 4336G generates 2 fragments of 244 bp and 69 bp that can be differentiated by electrophoresis in a 2% agarose gel. Each sample was ascribed to 1 of the haplogroups H, U, JT or Y, according to previously published protocols [Otaegui et al., 2004] . All mitochondrial primers (sequences available on request) were designed using the mitochondrial sequence AC_001807.
Linkage Studies
The linkage study was performed using the markers D8S277, D8S561, D8S1819 and D8S1825 with HEX-labeled primers and under the amplification conditions described in the GDB database (www.gdb.org). The PCR products were run in an ABIPRISM 310 genetic analyzer and analyzed with the Genescan software. The LOD score was calculated using the LCP software package.
Candidate Nuclear Gene Sequencing
The MTO1 gene was studied by direct sequencing of the coding exons in 1 patient (IV-28) from family 1, 1 asymptomatic individual that is a carrier of the A1555G mutation (III-5) from family 1, 1 patient from family 2 (III-5) and 1 healthy control unrelated with either family. The MTO1 primers (available on request) were designed using the sequence ENST00000323606.
The coding exons of the TRMU gene were also studied by direct sequencing in the following individuals: III-10, III-14, IV-40, V-2 and V-6 from family 1; III-9, IV-3 and IV-4 from family 2. The primers (available on request) were designed from the NC_ 000022.9 sequence. The presence of the G28T mutation was ascertained by PCR-RFLP using previously reported methods [Guan et al., 2006] . We examined this mutation in 256 healthy subjects. All sequencing reactions were carried out in a 310 or a 3130 Applied Biosystems genetic analyzer following the manufacturer's recommendations. Heteroplasmy observed using 2 techniques: Genescan and quantitative PCR (qPCR), compared with the electrophoresis results and the status of the individuals. The results of the RFLP in agarose gels are represented, whereby + indicates the presence of the mutation; a negative result is represented by -, while both symbols indicate that the RFLP shows the existence of heteroplasmy. NA = Not available.
Results

Heteroplasmy Levels
The data from the distinct analyses of heteroplasmy by Genescan, qPCR and electrophoresis were compared ( table 1 ). The Genescan technique detects levels of heteroplasmy between 0.8 and 98% in both families, finding more heteroplasmy in family 2. The study in controls with qPCR shows that the mutated probe was highly specific, giving an error of less than 1% (data not shown), this technique detects heteroplasmy only in family 2 (patients II-2 and III-1).
Mitochondrial SNP
None of the following mitochondrial mutations were found in any of the individuals studied: 961 insC, A4336G, A7445G, 7472 insC, T7510C or T7511C. Family 1 can be considered to be within the haplogroup JT and family 2 in the haplogroup H.
We characterized several homoplasmic changes in the 12S mitochondrial gene sequence ( table 2 ) . At nucleotide 750, we identified the A ] G transition in all samples analyzed (patients and controls). In contrast, a transversion (C ] G) was detected at position 1438 in the 2 families studied which was not evident in the controls, thereby segregating with the A1555G mutation. Furthermore, a T ] C transition was observed at position 1193 in family 2 but not in the other family.
Linkage and Nuclear Genes
The linkage analysis generated LOD scores between -0.5 and -2.5, ruling out the possible linkage of the chromosome 8 region with the disease (data available on request).
The sequence of MTO1 coding exons in the families studied did not show any difference in the families when compared with the controls. Likewise, no mutations were detected in the TRMU sequences except for the previously reported G28T mutations ( fig. 1, 2 ). This mutation was only present in family 1, where it was detected in 14 heterozygous individuals, 6 of whom were deaf and 8 healthy, and in 1 homozygous deaf subject. When 256 control subjects were analyzed, the proportion of heterozygotes was 12.1% and only 1 homozygous subject was identified (0.004%). 
Discussion
In 2 Spanish families suffering from maternally inherited neurosensory nonsyndromic deafness, we have analyzed different molecular changes that have been proposed as possible modifying factors associated with the A1555G mutation [el Schahawi et al., 1997] . Accordingly, we analyzed the degree of heteroplasmy, the presence of mitochondrial mutations, the proposed linkage to chromosome 8 and the role of the MTO1 and TRMU genes in these families and in healthy controls.
Heteroplasmy
Although the A1555G mutation is usually described as displaying a homoplasmic inheritance, individuals with heteroplasmic mutations have been described [del Castillo et al., 2003; el Schahawi et al., 1997] . Indeed, it was established that the mutated copies ranged from 3.75 to 96.60% in these heteroplasmic individuals and a pathogenic threshold was proposed between 20 and 52%. According to these conclusions, individuals with less than 20% of mutated copies would be asymptomatic, while individuals with more than 52% would be deaf. However, these affirmations do not correlate with the existence of healthy homoplasmic carriers of the mutation, occurring both in our families and in families reported elsewhere.
Instead of the classical densitometry methods, we have used 2 different techniques to measure the degree of heteroplasmy that avoid the use of radioactivity. A technical comparison of these 2 methods showed slight differences between the percentages obtained by Genescan or qPCR. In the Genescan approach, we used a restriction enzyme and a mismatch primer and these 2 conditions increase the variability of the technique, particularly in the values close to the extremes (0 and 100). Such problems were not associated with the use of qPCR, which displays less variability between replicates than Genescan. However, based on the control results, qPCR may have an error of 1% in terms of the estimation of the percentage level of mutation. Nevertheless, we believe that these 2 approaches are more realistic and more efficient than the densitometry approach.
In family 1 the mutation always appears as homoplasmic and while the pattern is clearly maternal, we found several carrier individuals without symptoms (III-10, III-21, III-15, IV-9, V-1 and V-8; fig 2 a) . Such asymptomatic carriers have also been found in other families, sustaining the existence of modulating factors. In contrast, heteroplasmic individuals were identified in family 2, the degree of heteroplasmy ranging between 71.186% (II-2) and 93.214% (III-1) . Similarly, asymptomatic homoplasmic carriers were identified (IV-4), which makes it impossible to establish a pathogenic threshold. The III-9 individual in this family should be a carrier of the mutation, but does not present the A1555G mutation. The genotype of this individual could be explained by nonequitable mitochondrial segregation during oogenesis in the mother which produces 2 or more ovule types with high levels of the mutation or with no mutated copies. This phenomenon, named bottleneck could be defined as the minimal number of mitochondrial genetic copies which occurs during oocyte formation and early development maximizing genetic drift for a heteroplasmic mother. This has been described in other mitochondrial diseases and nonequitable A1555G inheritance in the offspring of the carrier mothers was described by del Castillo et al. [2003] , supporting the possible occurrence of such a bottleneck. Moreover, we must take into account that our study was carried out on blood and thus the values obtained might not be representative of the affected tissue. Although several authors have tried to explain the mechanisms behind heteroplasmic inheritance, they still remain unclear [Battersby et al., 2003; Jenuth et al., 1996] .
In conclusion, the 2 families studied here carry a homoplasmic A1555G mutation on the one hand, while, on the other, the A1555G mutation is clearly heteroplasmic. In both families, homoplasmic carriers were identified that did not display any symptoms.
Mitochondrial Mutations
The MTRNR1 gene, in which the A1555G mutation is located, encodes the ribosomal 12S subunit. Hence, any other alteration in the sequence of this gene could affect the spatial conformation of this subunit and act in conjunction with the A1555G mutation to modulate its effects. Several different polymorphisms in this gene have been proposed as factors that might modulate this disease (see Introduction) and our data clearly indicate that the transition at nucleotide 750 can be considered as a polymorphism. This alteration appears with a similar frequency in both the healthy group of subjects and in the patients, and as such it is most likely a polymorphism rather than being related with the disease.
The C1438G transversion was also present in both families, but it was not identified in the control subjects. Moreover, this alteration has been described as a polymorphism in the MITOMAP database (www.mitomap. org). This transversion was also identified in another study on the relationship between mitochondria and deafness both in patients and control subjects [Yamasoba et al., 2002] . Accordingly, its potential implication in this disease remains unclear. Indeed, this substitution could be a population polymorphism that is found at greater frequency in carriers of the A1555G mutation. In order to evaluate this possibility, it will be necessary to determine the presence of this polymorphism in a larger number of A1555G carriers.
The nucleotide change 1193 (T ] C) appears exclusively in family 2 and is not included in the databases. It occurs at a nucleotide that is not highly conserved across evolution and that is found between structural helix 32 and 33 of the 12S subunit [Hickson et al., 1996] . This could be a rare polymorphism or, alternatively, a cofactor that modulates the effects of the A1555G mutation in an analogous manner to that seen for the secondary mutations in Leber's disease. However, the fact that the polymorphism segregates with the mutation does not explain the existence of asymptomatic carriers.
In summary, all mitochondrial changes encountered appear to be polymorphisms that are not related with the incomplete penetrance of the A1555G mutation. However, it will be important to carry out an analysis in larger series of patients to study the effects of these changes on the expression of the A1555G mutation.
Linkage Mutations and Candidate Genes
The proposed positive linkage of the 8q23 region [Bykhovskaya et al., 2001] has not been verified either by our data or in an earlier study [Finnila and Majamaa, 2003] , so the linkage of this region with the disease remains unclear.
The MTO1 gene, located in chromosome 6, has been proposed as a candidate gene to modulate the effects of the A1555G mutation. When mutated, it produces a deficit in the production of the respiratory channel, but only when the mtDNA of this cell carries the P R 454 mutation, equivalent to the human A1555G mtDNA mutation [Colby et al., 1998] . Like 2 other studies [Bykhovskaya et al., 2004; Finnila and Majamaa, 2003 ], we found no mutations in this gene in our families, and this gene could thus be discarded as a factor influencing this disease.
In 2006, it was proposed that the G28T mutation in the TRMU gene was associated with this disease [Guan et al., 2006] . This variant was found in around 25% of 2 cohorts carrying the A1555G mutation (1 Arab-Israeli and 1 European), while it was only present in 10% of Jewish and White controls. The mutation is not present in either controls or families suffering deafness in the Chinese population. Biochemically, the G28T mutation was shown to aggravate the mitochondrial dysfunction caused by the A1555G mutation [Guan et al., 2006] . According to this hypothesis, the G28T mutation acts in synergy with the mitochondrial mutation, lowering the mitochondrial translation process below the pathogenic threshold and thereby causing the phenotype.
In our cohorts, both of Spanish origin, we found the G28T mutation in 15 of 28 members in family 1. The mutation appears more frequently in this family than in normal controls, consistent with the proposed modifying role. However, in this family we did not find a correlation between the genotype and phenotype, since we found heterozygous individuals carrying the mutation with and without deafness. In some families, including 1 presented here, this mutation seems to be a marker for the pedigree, but it does not seem to be a modifying factor. More genes related to the complex set of factors involved in the mitochondrial translation process should be studied in relation with this phenomenon.
In our families, the A1555G mitochondrial mutation seems to be necessary but not sufficient to cause clinical symptoms. It therefore seems necessary to identify more susceptibility factors, probably SNP in nuclear genes related with mitochondrial metabolism, to explain the inheritance of this disease.
